Lipella Pharmaceuticals Inc
LIPO2.360USD
-0.345-12.75%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
6.02MCap. mercado
PérdidaP/E TTM
Más Datos de Lipella Pharmaceuticals Inc Compañía
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.
Información de la empresa
Símbolo de cotizaciónLIPO
Nombre de la empresaLipella Pharmaceuticals Inc
Fecha de salida a bolsaDec 20, 2022
Director ejecutivoDr. Jonathan H Kaufman, Ph.D.
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 20
Dirección400 N Lexington St Ste LL103
CiudadPITTSBURGH
Bolsa de valoresUS 'Other OTC' and Grey Market
PaísUnited States of America
Código postal15208
Teléfono14129010315
Sitio Webhttps://lipella.com/
Símbolo de cotizaciónLIPO
Fecha de salida a bolsaDec 20, 2022
Director ejecutivoDr. Jonathan H Kaufman, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan H Kaufman, Ph.D.
Dr. Jonathan H Kaufman, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
112.35K
--
Dr. Micheal B. Chancellor
Dr. Micheal B. Chancellor
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Byeong (Christopher) Kim, Ph.D.
Dr. Byeong (Christopher) Kim, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Birder, Ph.D.
Dr. Lori A. Birder, Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Johnston, CPA
Mr. Douglas Johnston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Naoki Yoshimura, M.D., Ph.D.
Dr. Naoki Yoshimura, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Chuck Harbey
Mr. Chuck Harbey
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Cohen
Mr. Daniel Cohen
Independent Director
Independent Director
--
--
Mr. Ryan Pruchnic
Mr. Ryan Pruchnic
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan H Kaufman, Ph.D.
Dr. Jonathan H Kaufman, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
112.35K
--
Dr. Micheal B. Chancellor
Dr. Micheal B. Chancellor
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Byeong (Christopher) Kim, Ph.D.
Dr. Byeong (Christopher) Kim, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Birder, Ph.D.
Dr. Lori A. Birder, Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Johnston, CPA
Mr. Douglas Johnston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Naoki Yoshimura, M.D., Ph.D.
Dr. Naoki Yoshimura, M.D., Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Kaufman (Jonathan H)
2.51%
Chancellor (Michael B.)
2.46%
Huang (Leaf)
1.55%
Sabby Management, LLC
1.35%
Tower Research Capital LLC
0.06%
Other
92.06%
Accionistas
Accionistas
Proporción
Kaufman (Jonathan H)
2.51%
Chancellor (Michael B.)
2.46%
Huang (Leaf)
1.55%
Sabby Management, LLC
1.35%
Tower Research Capital LLC
0.06%
Other
92.06%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
6.52%
Investment Advisor/Hedge Fund
1.35%
Hedge Fund
0.06%
Other
92.06%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
17
354.66K
7.94%
+95.32K
2025Q1
17
354.67K
11.68%
+95.33K
2024Q4
18
368.12K
30.45%
+2.26K
2024Q3
16
304.96K
29.23%
-126.37K
2024Q2
16
428.52K
49.20%
+108.86K
2024Q1
16
431.88K
52.07%
+138.44K
2023Q4
14
329.34K
44.74%
+70.35K
2023Q3
12
252.11K
34.85%
+66.33K
2023Q2
13
302.02K
42.06%
+116.08K
2023Q1
12
303.82K
42.31%
+124.35K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Kaufman (Jonathan H)
112.35K
2.51%
-4.00
-0.00%
Apr 09, 2025
Chancellor (Michael B.)
109.70K
2.46%
--
--
Apr 09, 2025
Huang (Leaf)
69.44K
1.55%
+60.76K
+700.03%
Mar 31, 2025
Sabby Management, LLC
60.33K
1.35%
+60.33K
--
Dec 31, 2024
Tower Research Capital LLC
2.71K
0.06%
+2.71K
--
Mar 31, 2025
MAI Capital Management, LLC
125.00
0%
--
--
Mar 31, 2025
BofA Global Research (US)
7.00
0%
--
--
Mar 31, 2025
Virtu Americas LLC
--
0%
-13.31K
-100.00%
Mar 31, 2025
HRT Financial LP
--
0%
-2.20K
-100.00%
Dec 31, 2024
Geode Capital Management, L.L.C.
--
0%
-3.11K
-100.00%
Dec 31, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Fecha
Tipo
Relación
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
